New approaches to treating fibrotic disorders have led to start-up financing for Promedior and Stromedix, two biotechs with early-stage in-licensed large molecule programs. To succeed where others have so-far failed the two newcomers will need innovative clinical strategies to accelerate their paths to proof-of-concept.
Christopher Morrison
When Michael Gilman, PhD, left his post as EVP of research at Biogen Inc. in late 2005, his goal...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.
The company, with partner Bristol Myers Squibb, has a three-wave development strategy for BNT-327: “establish, combine, broaden.”
Even though the company’s pharmaceutical business continues to do well, navigating some key stress points will be crucial for Bayer.
